New research reveals that neurons release a little-understood extracellular kinase called VLK to strengthen synaptic ...

Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...

Inhibikase Therapeutics, Inc. (NASDAQ: IKT) ('Inhibikase” or 'Company”), a clinical-stage pharmaceutical company developing ...

Phase 3 Study initiating in First Quarter of 2026Single Pivotal Study Accelerates Potential FDA Approval Timeline by Approximately 3 Years BOSTON ...

In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.

Some lung cancers manage to overcome a targeted drug therapy despite it showing initial success. Yale researchers have now ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the U.S. Food ...

Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) announced the companies have initiated the rolling submission of a New Drug Application to the U.S. Food and Drug Administration ...

On 13 November 2025, Merck Sharp & Dohme LLC initiated a study is to learn if people who receive patritumab deruxtecan (also ...

The FDA accepted a new drug application for zidesamtinib for previously treated locally advanced or metastatic ROS1-positive ...

Cullinan Therapeutics (CGEM) and Otsuka Holdings (OTSKF) subsidiaries Taiho Oncology and Taiho Pharmaceutical have initiated the rolling ...

NDA based on data from global ARROS-1 Phase 1/2 clinical trial FDA assigns PDUFA target action date of September 18, 2026 CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ ...